Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2008 December;33(4) > Minerva Endocrinologica 2008 December;33(4):313-27





A Journal on Endocrine System Diseases

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118




Minerva Endocrinologica 2008 December;33(4):313-27

language: English

Update on the diagnosis and therapy of distant metastases of differentiated thyroid carcinoma

Zanotti-Fregonara P. 1, Hindié E. 2, Faugeron I. 2, Moretti J. L. 2, Ravasi L. 1, Rubello D. 3, Toubert M. E. 2

1 DSV/I2BM/SHFJ/LMNRB, Commissariat à l’Energie Atomique, Orsay, France
2 Department of Nuclear Medicine, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
3 Nuclear Medicine Department - PET Unit, “S. Maria della Misericordia” Hospital, Istituto Oncologico Veneto (IOV), Rovigo, Italy


Differentiated thyroid cancer, when adequately treated, has an overall good prognosis. However, 10-15% of patients develop distant metastases. The presence of metastases is an important prognostic factor that negatively affects survival. For 131I-avid distant metastases, 131I therapy is a very effective treatment modality that induces complete remission in about a third of patients. These figures may be even higher in case of early diagnosis, when tumor burden is still limited. Additional measures may include surgery and/or external beam radiation therapy. Cytotoxic chemotherapy is largely ineffective in patients with progressive, poorly differentiated cancer. These patients should be candidates for trials with new molecularly targeted therapeutic agents. In this paper, a review of diagnostic modalities, prognostic factors and therapeutic options for patients with distant metastases is proposed. In particular, the prognostic value of the early discovery of metastatic disease will be underlined.

top of page

Publication History

Cite this article as

Corresponding author e-mail